BioCentury | Nov 11, 2013
Company News

A.P. Pharma management update

...as VP of finance and CFO, formerly VP of finance and chief accounting officer of Ista Pharmaceuticals Inc....
BioCentury | Jun 3, 2013
Company News

Bausch + Lomb ophthalmic news

...Bausch + Lomb said that its ISTA Pharmaceuticals Inc. subsidiary will pay about $34 million in civil and...
...in civil and criminal fines to the U.S. government to settle litigation involving conduct by ISTA...
...reimbursement. Bausch + Lomb, which acquired ISTA last June, said it will wind down the ISTA...
BioCentury | Apr 15, 2013
Clinical News

Prolensa bromfenac regulatory update

...rights to bromfenac through its acquisition of Ista Pharmaceuticals Inc. last year (see BioCentury, June 11, 2012). Ista...
BioCentury | Apr 8, 2013
Company News

Aerie Pharmaceuticals board of directors update

...Bedminster, N.J. Business: Ophthalmic Appointed: Vicente Anido as chairman, formerly president and CEO of Ista Pharmaceuticals Inc....
BioCentury | Apr 1, 2013
Company News

Revance management update

...as CFO and EVP of corporate development, formerly VP of corporate development and CFO of Ista Pharmaceuticals Inc....
BioCentury | Feb 18, 2013
Company News

Kolltan management update

...Cancer, Antibodies Hired: Jane Henderson as SVP and CBO, formerly VP of business development at Ista Pharmaceuticals Inc....
BioCentury | Jun 25, 2012
Clinical News

Prolensa bromfenac regulatory update

...rights to bromfenac through its acquisition of Ista Pharmaceuticals Inc. earlier this month (see BioCentury, June 11). Ista...
BioCentury | Jun 11, 2012
Company News

Bausch + Lomb, Ista deal

...Bausch + Lomb completed its acquisition of fellow ophthalmic company Ista for $9.10 per share in...
...or about $500 million (see BioCentury, April 2). Bausch + Lomb Inc. , Rochester, N.Y. Ista Pharmaceuticals Inc....
BioCentury | May 21, 2012
Clinical News

Prolensa bromfenac: Additional Phase III data

...at the Association for Research in Vision and Ophthalmology meeting in Fort Lauderdale. Last month, Ista...
...that Prolensa met the primary and secondary endpoints vs. placebo (see BioCentury, Oct. 17, 2011). Ista...
...acquired by Bausch + Lomb (see BioCentury, April 2). Croma-Pharma GmbH , Leobendorf, Austria Ista Pharmaceuticals Inc. (NASDAQ:ISTA...
BioCentury | May 14, 2012
Clinical News

Beposone: Phase II data

...adverse events reported. Patients received twice-daily Beposone, bepotastine, a steroid or placebo for 2 weeks. Ista...
...from Mitsubishi, which markets bepotastine as Talion for allergic rhinitis and urticaria in Japan. Ista Pharmaceuticals Inc. (NASDAQ:ISTA...
Items per page:
1 - 10 of 333
BioCentury | Nov 11, 2013
Company News

A.P. Pharma management update

...as VP of finance and CFO, formerly VP of finance and chief accounting officer of Ista Pharmaceuticals Inc....
BioCentury | Jun 3, 2013
Company News

Bausch + Lomb ophthalmic news

...Bausch + Lomb said that its ISTA Pharmaceuticals Inc. subsidiary will pay about $34 million in civil and...
...in civil and criminal fines to the U.S. government to settle litigation involving conduct by ISTA...
...reimbursement. Bausch + Lomb, which acquired ISTA last June, said it will wind down the ISTA...
BioCentury | Apr 15, 2013
Clinical News

Prolensa bromfenac regulatory update

...rights to bromfenac through its acquisition of Ista Pharmaceuticals Inc. last year (see BioCentury, June 11, 2012). Ista...
BioCentury | Apr 8, 2013
Company News

Aerie Pharmaceuticals board of directors update

...Bedminster, N.J. Business: Ophthalmic Appointed: Vicente Anido as chairman, formerly president and CEO of Ista Pharmaceuticals Inc....
BioCentury | Apr 1, 2013
Company News

Revance management update

...as CFO and EVP of corporate development, formerly VP of corporate development and CFO of Ista Pharmaceuticals Inc....
BioCentury | Feb 18, 2013
Company News

Kolltan management update

...Cancer, Antibodies Hired: Jane Henderson as SVP and CBO, formerly VP of business development at Ista Pharmaceuticals Inc....
BioCentury | Jun 25, 2012
Clinical News

Prolensa bromfenac regulatory update

...rights to bromfenac through its acquisition of Ista Pharmaceuticals Inc. earlier this month (see BioCentury, June 11). Ista...
BioCentury | Jun 11, 2012
Company News

Bausch + Lomb, Ista deal

...Bausch + Lomb completed its acquisition of fellow ophthalmic company Ista for $9.10 per share in...
...or about $500 million (see BioCentury, April 2). Bausch + Lomb Inc. , Rochester, N.Y. Ista Pharmaceuticals Inc....
BioCentury | May 21, 2012
Clinical News

Prolensa bromfenac: Additional Phase III data

...at the Association for Research in Vision and Ophthalmology meeting in Fort Lauderdale. Last month, Ista...
...that Prolensa met the primary and secondary endpoints vs. placebo (see BioCentury, Oct. 17, 2011). Ista...
...acquired by Bausch + Lomb (see BioCentury, April 2). Croma-Pharma GmbH , Leobendorf, Austria Ista Pharmaceuticals Inc. (NASDAQ:ISTA...
BioCentury | May 14, 2012
Clinical News

Beposone: Phase II data

...adverse events reported. Patients received twice-daily Beposone, bepotastine, a steroid or placebo for 2 weeks. Ista...
...from Mitsubishi, which markets bepotastine as Talion for allergic rhinitis and urticaria in Japan. Ista Pharmaceuticals Inc. (NASDAQ:ISTA...
Items per page:
1 - 10 of 333